Redefining Care through Regenerative Medicine
For addressing pain, injury, and the effects of disease, patients deserve non-addictive treatments that preserve quality of life. That’s why Bioregenex Life Sciences is committed to Providing human tissue-based products for healing and regeneration that adhere to the industry’s highest standards, going over and above current good tissue practice (cGTP) standards to ensure the safety of our products. With a focus on patient safety and continual drive to innovate, our tissue engineers leverage years of experience to extract, purify, and preserve tissues for use in advanced allograft technology. Our ultimate goal is to use the power of regenerative medicine to help people looking to heal after surgical intervention or disease, those who want to avoid narcotics for chronic pain, or those who have been let down by traditional avenues of care.
The Science behind a Growing Class of Therapies
Here at Bio-Regenex, we distribute and market placental tissue products that thump the healing potential of amniotic membrane. It is rich in growth with peptides associated with the generation of new tissue. Since amniotic tissues are also immunologically privileged, they are highly biocompatible. This helps in the reduction of risk of host rejection reactions which might complicate treatment and result in adverse effects.
Flowable & Membranes
NOTA™ is a flowable perinatal tissue allograft. It’s derived from human placental tissue and amniotic fluid, then cryopreserved to maintain the viability. NOTA™ retains the biologic functionality that ensures symmetrical development, growth, and repair of the soft tissue by acting as a biologic matrix for use in points of localized inflammation.
FASCEA™ is an amniotic allograft membrane, derived from human placental tissue, preserved to maintain the structural properties of the biologically active elements present in tissue regeneration. The amniotic membrane consists of a single layer of cuboidal epithelial cells firmly adhered to a thick basement membrane, which is attached to an avascular stromal layer.
FASCEA AC™ is an amniotic allograft membrane, containing the amnion and chorion layers, plus Wharton’s Jelly. The allograft is derived from human placental tissue, preserved to maintain the structural properties of the attractive, biologically active elements present in tissue regeneration
FASCEA OPTIC™ is a dehydrated, extracellular membrane allograft derived from human amniotic tissue for use as a scaffold for ocular repair. The allograft is derived from human placental tissue, preserved to maintain the structural properties of the attractive, biologically active elements present in tissue regeneration.
Coming from placental birth tissue of healthy and rigorously screened donors, placentally derived products are then processed based on their intended use
To prevent adverse immune reactions, preserved amniotic membrane contains immunoregulatory factors. That is why it is considered immunologically privileged. It doesn’t cause an immune reaction or inflammation in host tissues as well.
Amniotic membrane, which contains many substances including growth factors and cytokines interact to stimulate body’s stem cells. Once recruited, the body’s own stem cells begin to promote tissue healing.
Allograft is the transplant of an organ or tissue from one individual to another of the same species with a different genotype. Allografts are used in a number of procedures to save lives, repair limbs, relieve pain, or improve a patient’s quality of life.
Chorion is one of those two layers which makes amniotic membrane; other one is amnion. While amnion surrounds fetus, chorion is the outer layer that comes in contact with materna tissue.
Fast delivery times
A gelatinous substance that provides insulation and protection within the umbilical cord. Stem cells are present in Wharton’s jelly, as well as in umbilical cord blood. It contains one vein, which carries oxygenated, nutrient-rich blood to the fetus, and two arteries that carry deoxygenated, nutrient-depleted blood away.
References: 1. Tao H, Fan H. Implantation of amniotic membrane to reduce postlaminectomy epidural adhesions. Eur Spine J. 2009; 18(8):1202-12. 2. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999; 179(3):325-35. 3. Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and anti-inflammatory proteins in human amniotic membrane. Cornea. 2000; 19(3):348-52. 4. Islam R, Rahman S, Asaduzzaman SM, Rahman MS. Properties and Therapeutic Potential of Human Amniotic Membrane. Asian J Dermatol. 2015; 7(1):1-12. 5. Kubo M, Sonoda Y, Muramatsu R, Usui M. Immunogenicity of Human Amniotic Membrane in Experimental Xenotransplantation. Investigative Opth & Vis Sci. 2001; 42(7): 1539-46. 6. Niknejad H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian A. Properties of the Amniotic Membrane for Potential Use in Tissue Engineering. Eur Cells & Materials. 2008; 15: 88-99. Raines AL, Shih MS, Chua L, Su CW, Tseng SC. O’Connell J. Efficacy of Particulate Amniotic Membrane and Umbilical Cord Tissues in Attenuating Cartilage Destruction in an Osteoarthritis Model. Tissue Engineering Part A. 2017; 23(1-2). 8. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal Stem Cells in the Wharton’s Jelly of the Umbilical Cord. Stem Cells. 2004; 22: 1330-1337.